Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Stock Price Down 13.6% – Time to Sell?

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) shares dropped 13.6% on Tuesday . The company traded as low as $8.79 and last traded at $8.79. Approximately 94,962 shares were traded during trading, a decline of 6% from the average daily volume of 101,527 shares. The stock had previously closed at $10.17.

Analyst Ratings Changes

SGIOY has been the subject of a number of research reports. The Goldman Sachs Group raised Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a research report on Wednesday, April 8th. Zacks Research cut Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong sell” rating in a research note on Thursday, April 16th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Reduce”.

Shionogi & Co., Ltd. Unsponsored ADR Trading Down 14.8%

The company has a current ratio of 5.84, a quick ratio of 5.21 and a debt-to-equity ratio of 0.01. The firm has a market cap of $14.74 billion, a price-to-earnings ratio of 11.39, a PEG ratio of 0.75 and a beta of 0.10. The company has a fifty day moving average price of $10.57 and a 200-day moving average price of $9.77.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last announced its quarterly earnings results on Tuesday, May 12th. The company reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.03. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 13.70% and a net margin of 41.82%. As a group, research analysts expect that Shionogi & Co., Ltd. Unsponsored ADR will post 0.73 EPS for the current year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.